Is Cerebrolysin Useful in Psychiatry Disorders?

TL;DR

This review explores whether Cerebrolysin, a peptide mixture used for neurological disorders, could also be useful in treating psychiatric conditions like depression and autism.

Contribution

The paper provides a scoping review of Cerebrolysin's potential applications in psychiatry, highlighting its possible role in depression and autism.

Findings

Cerebrolysin may have limited but potential applications in psychiatry, particularly for depression and autism spectrum disorders.

It could help reduce adverse effects of neuroleptic treatments in psychiatric patients.

Very few studies have explored Cerebrolysin's use in mental disorders, indicating a need for more research.

Abstract

Background/Objectives: Cerebrolysin is a well-known mixture of peptides that has been used for many years, primarily in patients with neurological disorders. Thanks to its unique properties, this substance supports endogenous repair mechanisms and protects the brain from damaging factors. Cerebrolysin is most widely used in Eastern European countries. However, data on the potential use of cerebrolysin in mental disorders are difficult to find in the literature. This review focuses on the potential use of cerebrolysin in psychiatry, and two independent researchers searched three full-text medical article databases to compile it. Methods: To conduct this scoping review, two independent researchers searched three full-text article databases, Embase, Scopus, and Web of Science, by entering the following phrases: “cerebrolysin psychiatry”, “cerebrolysin depression”, “cerebrolysin mood”, “cerebrolysin bipolar”, “cerebrolysin schizophrenia”, and “cerebrolysin addiction”. Results: The results show that this specific substance could have a relatively small application in psychiatry. Conclusions: The limited amount of available research on the use of cerebrolysin suggests that it may have some significance in supporting the treatment of depression and autism spectrum disorders and alleviating adverse effects during treatment with neuroleptics.

Figures